Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip
Novavax | 4: Statement of changes in beneficial ownership of securities
諾瓦瓦克斯醫藥 | 4：持股變動聲明
牛牛AI助理已提取核心訊息
Filip Dubovsky, President of R&D at Novavax Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, post-transaction shareholding, and total value, were not disclosed in the announcement. This information is critical for investors to understand the insider activity within Novavax, which could potentially influence the company's stock performance.
Filip Dubovsky, President of R&D at Novavax Inc. [NVAX], was reported to have engaged in a transaction involving the company's stock on March 1, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, post-transaction shareholding, and total value, were not disclosed in the announcement. This information is critical for investors to understand the insider activity within Novavax, which could potentially influence the company's stock performance.
據報道，Novavax Inc. [NVAX] 研發總裁菲利普·杜波夫斯基於2024年3月1日參與了一項涉及該公司股票的交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格、交易後持股和總價值。這些信息對於投資者了解Novavax內部活動至關重要，這可能會影響公司的股票表現。
據報道，Novavax Inc. [NVAX] 研發總裁菲利普·杜波夫斯基於2024年3月1日參與了一項涉及該公司股票的交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格、交易後持股和總價值。這些信息對於投資者了解Novavax內部活動至關重要，這可能會影響公司的股票表現。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了